NCT03788291View on ClinicalTrials.gov

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2023

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
DRUG

Acalabrutinib

100 mg by mouth twice a day starting on day 8 of cycle 1

DRUG

Rituximab

Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT03788291 - Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter